Adding Farxiga (dapagliflozin) to standard care significantly reduced the risk of death or worsening heart failure in older ...

AstraZeneca saw 18% revenue growth in 2024, boosted by key drugs and global innovation. See here to know why we recommend a ...

The Prescription Drug Affordability Board is expected to set upper limits on some drugs this summer. With Expanded powers for ...

AZ is building a metabolic and cardiovascular franchise around Farxiga, which was first approved in type 2 diabetes and was added to the company’s portfolio of drugs after the company bought out ...

Farxiga is at the forefront of widening the use of SGLT2 inhibitors beyond their traditional role as treatments for type 2 diabetes. The company already picked up approvals for Farxiga to reduce ...

The Trump administration made a decidedly pro-industry statement on the Inflation Reduction Act (IRA). In an executive order issued Tuesday, President Donald Trump outlined changes to the Biden ...

It’s possible that they may play a role as a preventative measure in the future,” said Dr. Catriona Reddin told The Post.

New research suggests that GLP-1 drugs like Ozempic and Wegovy, commonly used for diabetes and weight loss, may also reduce the risk of Alzheimer's disease and dementia.

Germany's largest pharmaceutical company Boehringer Ingelheim on Wednesday reported a currency-adjusted 6.1% gain in 2024 revenues, buoyed by diabetes drug Jardiance and lung drug Ofev.

Ozempic may be known for weight loss, but new studies reveal it could also protect brain health and lower your risk of dementia and Alzheimer’s.

Maryland lawmakers have expanded a state board’s authority to set statewide upper-payment limits on high-cost prescriptions.